Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

685 Route 202/206 N, Suite 301, Bridgewater, United States

Motorhhead Aug. 2 at 12:36 PM

$BSLK $PAPL $VYNE $YOSH Attack? You mean how this stock promoter personally attacks ProfessorDman? I didn't attack as all I did was make an observation and to tell people to be careful. Besides why would I attack some stock promoter who provides great short ideas?!

0 · Reply

simbasana1 Aug. 2 at 10:27 AM

$BSLK $PAPL $VYNE $YOSH Please stop trying to denigrate a trader who has been consistently great over a long time. Some days are just red ones and yesterday was particularly red. From your other posts it shows you're a bear and that's okay but to attack other people is really mean-spirited. Don't be a d*ck!!!!

0 · Reply

simbasana1 Aug. 2 at 7:53 AM

$BSLK $PAPL $VYNE $YOSH I see that you're a short doing what some shorts do, lol!

1 · Reply

Motorhhead Aug. 2 at 1:53 AM

$BSLK $PAPL $VYNE $YOSH are all red after a mass pump today. I hope people out there are aware of certain promoters.

0 · Reply

Mnpois Aug. 2 at 1:10 AM

$VYNE gg.com

0 · Reply

dbr_island Aug. 2 at 12:13 AM

$VYNE 💯 And their cash vs debt 👇🤩

0 · Reply

dbr_island Aug. 1 at 11:58 PM

$VYNE 🚨LAST CALL🚨 BEFORE THIS UNDERVALUED TICKER GETS FOUND AND GOES BACK TOWARDS $1 🎯

0 · Reply

BigSqueezeComing Aug. 1 at 10:09 PM

$VYNE VYNE is shifting focus to VYN202, its next-gen oral BET inhibitor designed for systemic inflammatory and autoimmune diseases.

0 · Reply

BigSqueezeComing Aug. 1 at 10:07 PM

$VYNE VYNE is terminating the extension phase of the study and discontinuing further development in-house . Bad Phase 2b trial of Repibresib gel (VYN201) results.

0 · Reply

dbr_island Aug. 1 at 9:47 PM

$VYNE anyone here have at least 100,000 shares? $SONN $PBM $XCUR $OTRK are some of today’s AH movers

1 · Reply

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 4 weeks ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 3 months ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Apr 25, 2025, 11:55 AM EDT - 3 months ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 8:00 AM EDT - 3 months ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 20, 2025, 8:00 AM EDT - 4 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 5 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 5 months ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 5 months ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 7 months ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 7 months ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Sep 12, 2024, 8:00 AM EDT - 11 months ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 26, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 1 year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 1 year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

ALVR GRI IBIO

Jan 10, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 1 year ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 1 year ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 1 year ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 1 year ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 1 year ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 2 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Feb 28, 2023, 4:00 PM EST - 2 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

Feb 15, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

Feb 10, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Reverse Stock Split

Jan 9, 2023, 4:01 PM EST - 2 years ago

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

Dec 12, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event

Dec 7, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform

Dec 2, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Nov 18, 2022, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Motorhhead Aug. 2 at 12:36 PM

0 · Reply

simbasana1 Aug. 2 at 10:27 AM

0 · Reply

simbasana1 Aug. 2 at 7:53 AM

$BSLK $PAPL $VYNE $YOSH I see that you're a short doing what some shorts do, lol!

1 · Reply

Motorhhead Aug. 2 at 1:53 AM

$BSLK $PAPL $VYNE $YOSH are all red after a mass pump today. I hope people out there are aware of certain promoters.

0 · Reply

Mnpois Aug. 2 at 1:10 AM

$VYNE gg.com

0 · Reply

dbr_island Aug. 2 at 12:13 AM

$VYNE 💯 And their cash vs debt 👇🤩

0 · Reply

dbr_island Aug. 1 at 11:58 PM

$VYNE 🚨LAST CALL🚨 BEFORE THIS UNDERVALUED TICKER GETS FOUND AND GOES BACK TOWARDS $1 🎯

0 · Reply

BigSqueezeComing Aug. 1 at 10:09 PM

$VYNE VYNE is shifting focus to VYN202, its next-gen oral BET inhibitor designed for systemic inflammatory and autoimmune diseases.

0 · Reply

BigSqueezeComing Aug. 1 at 10:07 PM

$VYNE VYNE is terminating the extension phase of the study and discontinuing further development in-house . Bad Phase 2b trial of Repibresib gel (VYN201) results.

0 · Reply

dbr_island Aug. 1 at 9:47 PM

$VYNE anyone here have at least 100,000 shares? $SONN $PBM $XCUR $OTRK are some of today’s AH movers

1 · Reply

dbr_island Aug. 1 at 7:49 PM

$VYNE this is what can happen when you know what you own and stay the course👇🏆✅ ESPECIALLY when they have THIS MUCH cash compared to their current MC👇😮 WATCH AND LEARN

0 · Reply

hiTHit Aug. 1 at 6:17 PM

$VYNE Blocked by @dbr_island ... Another person who doesn't even believe the fairy tales he tells himself ...

1 · Reply

StockGoing Aug. 1 at 6:14 PM

$VYNE I want to remember why I bought this.

0 · Reply

hiTHit Aug. 1 at 5:20 PM

$VYNE Think on the bright side. I'm constantly selling, then buying at the bottom, thus increasing the number of my shares that have no value.

1 · Reply

dbr_island Aug. 1 at 4:39 PM

$TNON there’s that $1.70 break 💰💰💰 $VYNE patience should pay here ⏰🧨⏰ $LOBO $LXEH $MWYN let’s get it bulls

2 · Reply

dbr_island Aug. 1 at 4:09 PM

$TNON there’s that curl Break 1.70 and this could get interesting $VYNE is super undervalued I’m telling you WATCH AND LEARN LIKE

1 · Reply

dbr_island Aug. 1 at 4:02 PM

$LOBO now up over 83% $VYNE once the market realizes just how undervalued this is currently it should start reversing 👇🚨🚨🚨 WATCH SND LEARN $TNON $RAYA $BTAI what a day

0 · Reply

GthaFitTrader Aug. 1 at 3:45 PM

$VYNE buying more

1 · Reply

hiTHit Aug. 1 at 3:40 PM

$VYNE Names of CEOs who like to bankrupt the companies they manage: David, John, Adam, Eric, Michael, etc...

0 · Reply

dbr_island Aug. 1 at 3:34 PM

$LOBO now up over 43% $VYNE their cash alone could take this back to .70+

0 · Reply

dbr_island Aug. 1 at 3:33 PM

$LOBO there goes it up over 35% $VYNE keep doubting this as I 🚢📦📦📦📦 Like you did at $TNON $MWYN 👇💰💰💰 $IMAB watching

0 · Reply

dbr_island Aug. 1 at 2:18 PM

$VYNE 🚨UNDERVALUED ALERT🚨 $TNON is paying BIG 💰💰💰 VYNE shouldn’t be this low especially with its $PHLT $LOBO $RAYA what a day

0 · Reply

Market Cap	5.56M
Revenue (ttm)	500,000.00
Net Income (ttm)	-39.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,966.00%
Debt to Equity Ratio	0.00

Volume	2,957,600
Avg Vol	1,757,530
Day's Range	N/A - N/A
Shares Out	15.21M
Stochastic %K	1%
Beta	1.78
Analysts	Sell
Price Target	$7.50